Research

The results of the first Canadian study on the burden of disease in Alopecia Areata are now published! This research reveals the psychosocial and financial impacts of alopecia areata on patients and caregivers. Link to the full article is within.

On June 13th, a JAK inhibitor called Olumiant became the first FDA-approved treatment for alopecia areata. Read more and find out what this means for Canadians.